Drug profile · INN
rosiglitazone maleate
ROSIGLITAZONE MALEATE
rosiglitazone maleate (ROSIGLITAZONE MALEATE) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — rosiglitazone maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.84
Quick answer
rosiglitazone maleate (ROSIGLITAZONE MALEATE) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Peroxisome proliferator-activated receptor gamma agonist
Primary target: Peroxisome proliferator-activated receptor gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 7632841
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted -
US 7435741
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted
Frequently asked questions
What is rosiglitazone maleate?
rosiglitazone maleate (ROSIGLITAZONE MALEATE) is a peroxisome proliferator-activated receptor gamma agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rosiglitazone maleate?
ROSIGLITAZONE MALEATE is a marketed brand name for rosiglitazone maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rosiglitazone maleate?
rosiglitazone maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.